Cytokinetics announces ck-2017357 receives fast track designation from the fda for the potential treatment of amyotrophic lateral sclerosis
Cytokinetics, Incorporated announced that CK–2017357, its fast skeletal muscle troponin activator, has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the potential treatment of amyotrophic lateral sclerosis (ALS), also commonly known as Lou Gehrig's Disease. CK–2017357, the lead drug candidate from the company's skeletal sarcomere activator program, is currently in Phase II clinical trials intended to inform a potential registration program. Cytokinetics anticipates that results from two recently completed Phase II clinical trials, designed to assess the safety and tolerability of CK–2017357 in patients with ALS, will be presented at the American Academy of Neurology 64th Annual Meeting in New Orleans, LA on April 2012.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.